Why DIANON Sale Alters Anatomic Path Market

LabCorp’s $598 million investment is a major bet on AP-based diagnostics

CEO SUMMARY: By acquiring DIANON Systems, LabCorp raises the level of competition for tissue specimens originating in physicians’ offices. LabCorp’s acquisition is also a validation of predictions that cancer diagnostics will be a high-growth segment of laboratory medicine. Anatomic pathologists have ample warning that new national competitors will soon attempt to capture local physician accounts. …

Why DIANON Sale Alters Anatomic Path Market Read More »

This post is only available to members.



You are reading premium content from The Dark Report, your primary resource for running an efficient and profitable laboratory.

Get Unlimited Access to The Dark Report absolutely FREE!

You have read 0 of 1 of your complimentary articles this month

Privacy Policy: We will never share your personal information.